Frontiers in Pharmacology (May 2020)
Corrigendum: The Role of the FMN-Domain of Human Cytochrome P450 Oxidoreductase in Its Promiscuous Interactions With Structurally Diverse Redox Partners
- Francisco Esteves,
- Diana Campelo,
- Bruno Costa Gomes,
- Philippe Urban,
- Sophie Bozonnet,
- Thomas Lautier,
- José Rueff,
- Gilles Truan,
- Michel Kranendonk
Affiliations
- Francisco Esteves
- Centre for Toxicogenomics and Human Health (ToxOmics), Genetics, Oncology and Human Toxicology, NOVA Medical School, Faculty of Medical Sciences, Universidade NOVA de Lisboa, Lisbon, Portugal
- Diana Campelo
- Centre for Toxicogenomics and Human Health (ToxOmics), Genetics, Oncology and Human Toxicology, NOVA Medical School, Faculty of Medical Sciences, Universidade NOVA de Lisboa, Lisbon, Portugal
- Bruno Costa Gomes
- Centre for Toxicogenomics and Human Health (ToxOmics), Genetics, Oncology and Human Toxicology, NOVA Medical School, Faculty of Medical Sciences, Universidade NOVA de Lisboa, Lisbon, Portugal
- Philippe Urban
- Centre National de la Recherche Scientifique, Institut National de la Recherche Agronomique, Institut National des Sciences Appliquées de Toulouse, Toulouse Biotechnology Institute, Université de Toulouse, Toulouse, France
- Sophie Bozonnet
- Centre National de la Recherche Scientifique, Institut National de la Recherche Agronomique, Institut National des Sciences Appliquées de Toulouse, Toulouse Biotechnology Institute, Université de Toulouse, Toulouse, France
- Thomas Lautier
- Centre National de la Recherche Scientifique, Institut National de la Recherche Agronomique, Institut National des Sciences Appliquées de Toulouse, Toulouse Biotechnology Institute, Université de Toulouse, Toulouse, France
- José Rueff
- Centre for Toxicogenomics and Human Health (ToxOmics), Genetics, Oncology and Human Toxicology, NOVA Medical School, Faculty of Medical Sciences, Universidade NOVA de Lisboa, Lisbon, Portugal
- Gilles Truan
- Centre National de la Recherche Scientifique, Institut National de la Recherche Agronomique, Institut National des Sciences Appliquées de Toulouse, Toulouse Biotechnology Institute, Université de Toulouse, Toulouse, France
- Michel Kranendonk
- Centre for Toxicogenomics and Human Health (ToxOmics), Genetics, Oncology and Human Toxicology, NOVA Medical School, Faculty of Medical Sciences, Universidade NOVA de Lisboa, Lisbon, Portugal
- DOI
- https://doi.org/10.3389/fphar.2020.00773
- Journal volume & issue
-
Vol. 11
Abstract
No abstracts available.Keywords
- NADPH cytochrome P450 oxidoreductase (CPR)
- cytochrome P450 monooxygenases (CYP)
- FMN-domain
- binding motifs
- redox partner
- protein–protein interaction
